On November 5, 2025, argenx SE announced that Health Canada approved VYVGART SC (efgartigimod alfa injection) as a monotherapy for adults with active chronic inflammatory demyelinating polyneuropathy ...

VYVGART ® SC is first and only neonatal Fc receptor blocker approved to treat CIDP Authorization is based on global ADHERE study, the largest clinical trial in CIDP to date First novel, targeted ...

The MarketWatch News Department was not involved in the creation of this content. -- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authorization is based on ...

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...

After being told he might not walk for two years, the longtime Little League football coach fought through treatment to ...

The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Read more ...

The S&P 1500 Health Care Index gained 1.9% in September, underperforming the S&P 500, which advanced 3.7%. Read more here.

The American Gastroenterological Association (AGA) has released a comprehensively updated clinical guideline on the ...

The previous quarter showed revenue of $396k and a loss of $36.77 million. This valuation on DNTH is abysmal. Price-to-Sales ...

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients ...

Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...

Arrowhead Clinic Midtown Atlanta has expanded its walk-in services to provide immediate chiropractic evaluation and treatment for individuals experiencing whiplash and other injuries following ...